EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma

Mei-Chee Tai, Leonidas E Bantis, Gargy Parhy, Taketo Kato iD, Ichidai Tanaka iD, Chi-Wan Chow, Junya Fujimoto, Carmen Behrens, Tetsunari Hase, Koji Kawaguchi iD, Johannes F Fahrmann, Edwin J Ostrin iD und 6 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25042331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Mei-Chee Tai und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Circulating MicroRNA, Adenocarcinoma of Lung, MicroRNAs, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, United States Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early-stage lung adenocarcinoma (LUAD) patients remain at substantial risk for recurrence and disease-related death, highlighting the unmet need of biomarkers for the assessment and identification of those in an early stage who would likely benefit from adjuvant chemotherapy. To identify circulating miRNAs useful for predicting recurrence in early-stage LUAD, we performed miRNA microarray analysis with pools of pretreatment plasma samples from patients with stage I LUAD who developed recurrence or remained recurrence-free during the follow-up period. Subsequent validation in 85 patients with stage I LUAD resulted in the development of a circulating miRNA panel comprising miR-23a-3p, miR-320c, and miR-125b-5p and yielding an area under the curve (AUC) of 0.776 in predicting recurrence. Furthermore, the three-miRNA panel yielded an AUC of 0.804, with a sensitivity of 45.8% at 95% specificity in the independent test set of 57 stage I and II LUAD patients. The miRNA panel score was a significant and independent factor for predicting disease-free survival (p < 0.001, hazard ratio [HR] = 1.64, 95% confidence interval [CI] = 1.51–4.22) and overall survival (p = 0.001, HR = 1.51, 95% CI = 1.17–1.94). This circulating miRNA panel is a useful noninvasive tool to stratify early-stage LUAD patients and determine an appropriate treatment plan with maximal efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating MicroRNAAdenocarcinoma of LungMicroRNAsLung NeoplasmsHumansBiomarkers, Tumor

Stichwörter der Autor:innen

lung adenocarcinomamicroRNAplasmarecurrencesurvival

Substanzen

Circulating MicroRNABiomarkers, TumorMicroRNAs

Autor:innen und Institutionen

  • Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, KS 66160, USA.
  • Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan.
  • Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan.
  • Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ORCID-Profile: Taketo Kato, Ichidai Tanaka, Koji Kawaguchi, Edwin J Ostrin, Toyofumi F Chen-Yoshikawa, Yoshinori Hasegawa, Ayumu Taguchi

Förderung

  • NCI NIH HHS
  • NIH HHS
  • United States Department of Defense
  • NIH/NCI
  • Cancer Prevention and Research Institute of Texas
  • MD Anderson Moon Shots Program
  • MD Anderson start-up funds
  • Japan Society for the Promotion of Science

Zitieren

APA

Tai, M. C., Bantis, L. E., Parhy, G., Kato, T., Tanaka, I., Chow, C. W., Fujimoto, J., Behrens, C., Hase, T., Kawaguchi, K., Fahrmann, J. F., Ostrin, E. J., Yokoi, K., Chen-Yoshikawa, T. F., Hasegawa, Y., Hanash, S. M., Wistuba, I. I., & Taguchi, A. (2024). Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25042331

Vancouver

Tai MC, Bantis LE, Parhy G, Kato T, Tanaka I, Chow CW, et al. Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25042331

BibTeX
@article{Tai2024,
  author = {Tai, Mei-Chee and Bantis, Leonidas E and Parhy, Gargy and Kato, Taketo and Tanaka, Ichidai and Chow, Chi-Wan and Fujimoto, Junya and Behrens, Carmen and Hase, Tetsunari and Kawaguchi, Koji and Fahrmann, Johannes F and Ostrin, Edwin J and Yokoi, Kohei and Chen-Yoshikawa, Toyofumi F and Hasegawa, Yoshinori and Hanash, Samir M and Wistuba, Ignacio I and Taguchi, Ayumu},
  title = {Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25042331}
}
Kostenlos starten →